Fluorouracil (Systemic) and Mitomycin Intravenous
Determining the interaction of Fluorouracil (Systemic) and Mitomycin Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:The use of mitoMYcin has been associated with a condition known as hemolytic uremic syndrome (HUS), and using it with fluorouracil may increase that risk. HUS is a disorder where red blood cells are destroyed by toxic substances produced by an infection. The damaged red blood cells can clog the filtering system in the kidneys and cause kidney failure. Fatality may occur in up to 50% of cases. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Consult with your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Fluorouracil may increase the risk of hemolytic uremic syndrome (HUS) associated with mitomycin C. HUS can be fatal in up to 50% of affected patients. The mechanism of this interaction and incidence are unknown. It has been suggested that the symptoms may be exacerbated by blood transfusions.
MANAGEMENT: Patients should be carefully monitored with frequent and regular CBCs as well as serum BUN and creatinine measurements. The authors of a case report suggest that treatment should be interrupted at the first signs of intravascular hemolysis, proteinuria, and rising urea.
- Higashihara J, Berens ME, Collins LA, Homesley HD, Welander CE "Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay." Gynecol Oncol 48 (1993): 171-9
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
- "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
Generic Name: fluorouracil
Brand name: Adrucil
Synonyms: Fluorouracil (injection)
Generic Name: mitomycin
Brand name: Mutamycin
Synonyms: Mitomycin, MitoMYcin (Systemic)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fluorouracil (Systemic)-Mitotane
- Fluorouracil (Systemic)-Mitoxantrone
- Fluorouracil (Systemic)-Mitoxantrone Hydrochloride
- Fluorouracil (Systemic)-Mitoxantrone Injection Concentrate
- Fluorouracil (Systemic)-Mitoxantrone Intravenous, Injection
- Fluorouracil (Systemic)-Mitrazol
- Mitomycin Intravenous-Fluorouracil injection
- Mitomycin Intravenous-Fluorouracil Intravenous, Injection
- Mitomycin Intravenous-Fluovix
- Mitomycin Intravenous-Fluoxetine
- Mitomycin Intravenous-Fluoxetine and olanzapine
- Mitomycin Intravenous-Fluoxetine Capsules